Heron Therapeutics Inc (NASDAQ:HRTX) – Leerink Swann lifted their FY2019 EPS estimates for shares of Heron Therapeutics in a research note issued on Tuesday, Zacks Investment Research reports. Leerink Swann analyst J. Gerberry now forecasts that the biotechnology company will post earnings of ($0.57) per share for the year, up from their prior estimate of ($0.75). Leerink Swann has a “Buy” rating and a $21.00 price objective on the stock. Leerink Swann also issued estimates for Heron Therapeutics’ FY2020 earnings at $1.00 EPS and FY2021 earnings at $3.05 EPS.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Thursday, February 23rd. The biotechnology company reported ($1.22) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.17) by $0.05. The business earned $1.28 million during the quarter, compared to analyst estimates of $1.07 million.
WARNING: This story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2017/04/21/leerink-swann-equities-analysts-lift-earnings-estimates-for-heron-therapeutics-inc-hrtx-updated-updated.html.
HRTX has been the subject of several other reports. Zacks Investment Research downgraded shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 10th. Cantor Fitzgerald set a $34.00 target price on shares of Heron Therapeutics and gave the company a “buy” rating in a research note on Thursday, January 12th. Jefferies Group LLC restated a “buy” rating and issued a $29.00 target price on shares of Heron Therapeutics in a research note on Monday, April 10th. Cowen and Company restated a “buy” rating and issued a $40.00 target price on shares of Heron Therapeutics in a research note on Friday, January 6th. Finally, Needham & Company LLC initiated coverage on shares of Heron Therapeutics in a research note on Monday, February 27th. They issued a “buy” rating and a $28.00 target price for the company. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $34.38.
Heron Therapeutics (NASDAQ:HRTX) traded down 3.18% during mid-day trading on Thursday, reaching $15.20. The company’s stock had a trading volume of 353,463 shares. Heron Therapeutics has a one year low of $12.21 and a one year high of $24.00. The firm’s 50 day moving average is $14.51 and its 200-day moving average is $14.75.
Several large investors have recently bought and sold shares of HRTX. Pacad Investment Ltd. bought a new stake in Heron Therapeutics during the fourth quarter valued at approximately $155,000. Wells Fargo & Company MN increased its stake in Heron Therapeutics by 20.0% in the third quarter. Wells Fargo & Company MN now owns 11,167 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 1,858 shares during the last quarter. Highbridge Capital Management LLC increased its stake in Heron Therapeutics by 1.6% in the fourth quarter. Highbridge Capital Management LLC now owns 15,697 shares of the biotechnology company’s stock valued at $206,000 after buying an additional 252 shares during the last quarter. Nationwide Fund Advisors increased its stake in Heron Therapeutics by 11.3% in the first quarter. Nationwide Fund Advisors now owns 21,972 shares of the biotechnology company’s stock valued at $330,000 after buying an additional 2,233 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in Heron Therapeutics during the fourth quarter valued at approximately $353,000.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Heron Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.